Karen M. Soares - 15 Sep 2026 Form 4 Insider Report for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

Reporting relationship: Chief Legal Officer
Issuer ticker: CLOV
Reported as of: 15 Sep 2026
Net transaction value: -$32,724
SEC form: 4
Accepted by SEC: 15 Sep 2026, 20:11:21 UTC
Prior SEC filing: 13 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/Peter J. Rivas as attorney-in-fact for Karen M. Soares

Key filing fact

Karen M. Soares filed Form 4 for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) on 15 Sep 2026.

Key facts

This page summarizes Karen M. Soares's Form 4 filing for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 15 Sep 2026, 20:11.

Change

Previous filing in this sequence was filed on 13 Aug 2026.
Current net transaction value: -$32,724.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001999086 Primary reporting owner

Soares Karen

Relationship: Chief Legal Officer
Address: C/O CLOVER HEALTH INVESTMENTS, CORP., NOT APPLICABLE, WILMINGTON
Signature: /s/Peter J. Rivas as attorney-in-fact for Karen M. Soares
Signature date: 15 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLOV transaction

Class A Common Stock

Sale

Transaction value: $32,724
Shares: -6,846
Change %: -0.42%
Price: $4.78
Shares after: 1,607,371
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The sales reported on this Form 4 represent shares of Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the final vesting of 6.25% of restricted stock units originally granted to the Reporting Person on September 15, 2022. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Footnote F2

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.70 to $4.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.